Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients

NCT02421172 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa (Acne Inversa)

Interventions

BIOLOGICAL: CJM112
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals